LEXINGTON, Mass.--(BUSINESS WIRE)--March 6, 2006--Cubist Pharmaceuticals, Inc. (Nasdaq: CBST) today announced that NASDAQ has halted trading of Cubist common stock. The Anti-Infective Drug Advisory Committee to the U.S. Food and Drug Administration (FDA) meets today to review and discuss the Supplemental New Drug Application (sNDA) for CUBICIN(R) (daptomycin for injection) seeking approval as treatment for Staphylococcus aureus (S. aureus) bacteremia including those with known or suspected endocarditis.
